

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3086703

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATHWAY THERAPEUTICS, INC.	06/13/2013
RECEIVING PARTY DATA	
Name:	VETDC, INC.
Street Address:	320 EAST VINE DRIVE
Internal Address:	SUITE 123-5A
City:	FORT COLLINS
State/Country:	COLORADO
Postal Code:	80524
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14324570
CORRESPONDENCE DATA	
Fax Number:	(303)268-0065
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	303-268-0066
Email:	sharward@sbiplaw.com
Correspondent Name:	SWANSON & BRATSCHEUN, LLC
Address Line 1:	8210 SOUTHPARK TERRACE
Address Line 4:	LITTLETON, COLORADO 80120
ATTORNEY DOCKET NUMBER:	0606.01US-C2 ASSIGNMENT 4
NAME OF SUBMITTER:	MARY BREEN SMITH
SIGNATURE:	/Mary Breen Smith/
DATE SIGNED:	10/29/2014
Total Attachments: 6	
source=Assignment_PathwayInc_VetDC#page1.tif	
source=Assignment_PathwayInc_VetDC#page2.tif	
source=Assignment_PathwayInc_VetDC#page3.tif	
source=Assignment_PathwayInc_VetDC#page4.tif	
source=Assignment_PathwayInc_VetDC#page5.tif	
source=Assignment_PathwayInc_VetDC#page6.tif	

PATENT

6/13/13 11:05 AM

ASSIGNMENT OF PATENTS

WHEREAS, **PATHWAY THERAPEUTICS, INC.**, a Delaware corporation, with a place of business at 409 Illinois Street, San Francisco, CA 94158 ("**Assignor**"), is the sole and exclusive owner of the issued patents and patent applications listed in Schedule 2.1(d) of the Asset Purchase Agreement entered into between the Assignor and Assignee on June 13, 2013;

WHEREAS, **VETDC, INC.**, a Delaware company, with a place of business at 320 East Vine Drive, Suite 123-5A, Fort Collins, CO 80524 ("**Assignee**") is desirous of obtaining the full and entire right, title and interest for all countries throughout the world, in, to and under said patents and patent applications;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, **Assignor** has sold, assigned, transferred and set over to **Assignee**, its assigns and successors in interest, the full and entire right, title and interest, for all countries throughout the world, in, to and under those certain issued patents and patent applications listed in Schedule 2.1(d) of the Asset Purchase Agreement together with the inventions described in said patents and patent applications, and together with all continuation, divisional, continuation-in-part, reexamination and reissue applications, and all corresponding foreign applications and patents which may be filed thereon, including the right to prosecute such patent applications as well as to claim priority from any application identified in Schedule 2.1(d), and together with the right to sue for any past infringement, for the sole use and behalf of **Assignee**, its assigns and successors in interest, to the full end of the term for which each said patent and patent application is granted, as fully and entirely as the same would have been held by **Assignor** had this assignment and sale not been made. **Assignor** hereby agrees that **Assignor**, along with its employees, agents and assignors will sign all lawful papers, including, without limitation, all divisional, continuation, continuation-in-part, renewal, extension, reexamination and reissue applications, and make all rightful oaths in execution thereof.

IN WITNESS WHEREOF, **Assignor** has caused this Assignment to be executed by its duly authorized representative this 13th day of June, 2013.

PATHWAY THERAPEUTICS, INC.

By: _____

Name: Julie Cherrington

Title: President and CEO

see Attached Acknowledgment, June 13, 2013.

PATENT

REEL: 034063 FRAME: 0854


6/13/13 11:05 AM

STATE OF CALIFORNIA)
) ss.
COUNTY OF San Francisco)

On June 13, 2013 before me, Elvis Madelis Valladares, Notary Public, personally appeared Tolie Michele Cherrington, who proved to me on the basis of satisfactory evidence to be the person(x) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(x), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing is true and correct.

WITNESS my hand and official seal.



Elvis Madelis Valladares
Signature of Notary Public

ACCEPTED by Assignee.

Date: _____

Steven Roy
President and CEO

STATE OF Colorado)
) ss.
COUNTY OF _____)

The foregoing instrument was acknowledged before me this ___ day of _____, by Steven Roy.

Witness my hand and official seal.

My commission

expires: _____

Notary Public

STATE OF CALIFORNIA)
) ss.
COUNTY OF _____)

On _____ before me, _____, Notary Public, personally appeared _____, who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing is true and correct.

WITNESS my hand and official seal.

Place Notary Seal Above

Signature of Notary Public

ACCEPTED by Assignee.

Date: 13 June 2013



Steven Roy
President and CEO


STATE OF Colorado)
) ss.
COUNTY OF Boulder)

The foregoing instrument was acknowledged before me this 13th day of June, by Steven Roy.

Witness my hand and official seal.

My commission

expires: 2/17/2014



Notary Public

Schedule 2.1(d)

Patent Rights

Jones Day CAM (Docket)	Pat Type	Serial No. (Publication No.)	Filed (Pub. Date)	Title	Status	Assignee
322610- 888003 (12633- 003-888)	U.S. PROV.	61/164,359	03/27/09	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Expired	Pathway
322610- 888006 (12633- 006-888)	U.S. PROV.	61/223,687 (Update of 61/164,359)	07/07/09	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Expired	Pathway
322610- 888008 (12633- 008-888)	U.S. PROV.	61/247,454 (Update of 61/223,687)	09/30/09	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Expired	Pathway
322610- 001008 (12633- 008-001)	CA	2,756,067	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 007008 (12633- 008-007)	AU	2010229468	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 008008 (12633- 008-008)	NZ	595372	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 009008 (12633- 008-009)	MX	MX/a/2011/010105	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 012008 (12633- 008-012)	JP	2012-501953	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 019008 (12633- 008-019)	RU	2011143359	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway

Jones Day CAM (Docket)	Pat Type	Serial No. (Publication No.)	Filed (Pub. Date)	Title	Status	Assignee
322610- 023008 (12633- 008-023)	HK	12107352.3	07/26/12	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 036008 (12633- 008-036)	AR	10 01 00996	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 037008 (12633- 008-037)	BR	To be assigned	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 055008 (12633- 008-055)	SG	201106880-6	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 056008 (12633- 008-056)	IN	7763/CHENP/2011	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 146008 (12633- 008-146)	CN	201080023218.9	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 147008 (12633- 008-147)	ZA	2011/06698	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 158008 (12633- 008-158)	IL	215227	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 185008 (12633- 008-185)	TW	099109225	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 187008 (12633- 008-187)	KR	2011-7025448	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway

Jones Day CAM (Docket)	Pat Type	Serial No. (Publication No.)	Filed (Pub. Date)	Title	Status	Assignee
322610- 227008 (12633- 008-227)	EP	10733052.4	03/26/10	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	Pathway
322610- 228008 (12633- 008-228)	PCT	PCT/NZ2010/000060 (WO 2010/110685)	03/26/10 (09/30/10)	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Completed	Pathway
322610- 999008 (12633- 008-999)	U.S.	12/748,251 (US 2010/0249099)	03/26/10 (09/30/10)	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	To be issued on June 11, 2013.	Pathway
322610- 999022 (12633- 022-999)	U.S. DIV	13/914.385	06/10/13	Pyrimidinyl and 1,3,5- Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy	Pending	